Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Oseltamivir (Tamiflu) significantly reduces ICU admissions and shortens hospital stays in children hospitalized with influenza, a large retrospective study found. Crucially, the benefit held even when treatment was started more than 5 days after symptoms began — challenging the common belief that antivirals lose their effectiveness after 48 hours. Experts say the findings support treating all hospitalized kids with flu, regardless of when they present.
Tamiflu cuts ICU risk in kids with flu — even when started late
A large retrospective study published in JAMA Pediatrics found that oseltamivir (Tamiflu) significantly reduces the risk of ICU admission and shortens hospital stays in children hospitalized with influenza. Analyzing data from over 7,000 pediatric flu hospitalizations across 13 U.S. states spanning nine flu seasons (2014–2023), researchers found that treated children were 31% less likely to be admitted to the ICU compared to untreated peers.
Perhaps the most notable finding: the protective effect persisted regardless of when treatment started — including in children who began oseltamivir more than 5 days after symptom onset. This challenges the widely held assumption that antivirals are only useful within the first 48 hours of illness. Researchers noted that hospitalized children represent a distinct population where the benefit of treatment extends well beyond the early illness window.
By the numbers:
Why it matters: These findings send a clear message to clinicians: don't hold back on oseltamivir for hospitalized children, even if they've been sick for several days. The authors emphasize that healthcare professionals should encourage caregivers to seek care early and urgently consider oseltamivir for all children and adolescents hospitalized with suspected or confirmed influenza.
